Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration

Clin Pharmacokinet. 2023 May;62(5):715-724. doi: 10.1007/s40262-023-01230-w. Epub 2023 Mar 27.

Abstract

Background and objective: In neonates, β-Lactam antibiotics are almost exclusively administered by intermittent infusion. However, continuous or prolonged infusion may be more beneficial because of the time-dependent antibacterial activity. In this pharmacokinetic/pharmacodynamic simulation study, we aimed to compare treatment with continuous, extended and intermittent infusion of β-lactam antibiotics for neonates with infectious diseases.

Methods: We selected population pharmacokinetic models of penicillin G, amoxicillin, flucloxacillin, cefotaxime, ceftazidime and meropenem, and performed a Monte Carlo simulation with 30,000 neonates. Four different dosing regimens were simulated: intermittent infusion in 30 min, prolonged infusion in 4 h, continuous infusion, and continuous infusion with a loading dose. The primary endpoint was 90% probability of target attainment (PTA) for 100% ƒT>MIC during the first 48 h of treatment.

Results: For all antibiotics except cefotaxime, continuous infusion with a loading dose resulted in a higher PTA compared with other dosing regimens. Sufficient exposure (PTA >90%) using continuous infusion with a loading dose was reached for amoxicillin (90.3%), penicillin G (PTA 98.4%), flucloxacillin (PTA 94.3%), cefotaxime (PTA 100%), and ceftazidime (PTA 100%). Independent of dosing regimen, higher meropenem (PTA for continuous infusion with a loading dose of 85.5%) doses might be needed to treat severe infections in neonates. Ceftazidime and cefotaxime dose might be unnecessarily high, as even with dose reductions, a PTA > 90% was retained.

Conclusions: Continuous infusion after a loading dose leads to a higher PTA compared with continuous, intermittent or prolonged infusion, and therefore has the potential to improve treatment with β-lactam antibiotics in neonates.

MeSH terms

  • Amoxicillin
  • Anti-Bacterial Agents / pharmacokinetics
  • Cefotaxime
  • Ceftazidime
  • Communicable Diseases*
  • Floxacillin*
  • Humans
  • Infant, Newborn
  • Infusions, Intravenous
  • Meropenem
  • Microbial Sensitivity Tests
  • Monobactams
  • Monte Carlo Method

Substances

  • Floxacillin
  • Meropenem
  • Ceftazidime
  • Anti-Bacterial Agents
  • Cefotaxime
  • Monobactams
  • Amoxicillin